Daniel SW Tan
机构: National Cancer Centre Singapore
每年引用次数
引用次数
引用: 21,159
H-指数: 61
I10-指数 : 161
出版物: 486
Abstract B161: Pseudoprogression of metastatic abdominal wall nodules in a patient with lung carcinoma treated with pembrolizumab
Tiffany Hennedige , Daniel Tan , Narayanan Gopalakrishna Iyer , Amit Jain
Cancer immunology research 7
2019
Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer
Christian Rolfo , Philip Mack , Giorgio V Scagliotti , Charu Aggarwal
Journal of Thoracic Oncology 16 ( 10) 1647 -1662
149
2021
Abstract CT559: Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification
Yi-Long Wu , Ji-Youn Han , Terufumi Kato , Fabrice Barlesi
Cancer Research 82 ( 12\_Supplement) CT559 -CT559
2022
EP294/# 883 Elimusertib, an oral ataxia telangiectasia and RAD3-related inhibitor, in advanced gynecologic cancers with DNA damage response defects
David S Tan , Vincent Castonguay , Gregory Cote , Johann S De Bono
International Journal of Gynecologic Cancer 32 ( Suppl 3)
2022
Heterogeneity of mutation calling and annotation: a survey of cancer next-generation sequencing initiatives by the Global Alliance for Genomics and Health (GA4GH)
Daniel J Vis , Jeremy Lewin , Lillian Siu , Rachel Liao
Cancer Research 76 ( 14_Supplement) 5287 -5287
2016
Characterization and first-in-human data of CLR457, an orally bioavailable pan-class I PI3-Kinase inhibitor
James J Harding , Todd M Bauer , Daniel Tan , Philippe L Bedard
Investigational new drugs
2018
Fragle: Universal ctDNA quantification using deep learning of fragmentomic profiles
Guanhua Zhu , Chowdhury Rafeed Rahman , Victor Getty , Probhonjon Baruah
bioRxiv 2023.07. 28.550922 -2023.07. 28.550922
2023
Expert consensus recommendations on biomarker testing in metastatic and nonmetastatic NSCLC in Asia
Tetsuya Mitsudomi , Daniel Tan , James Chih-Hsin Yang , Myung-Ju Ahn
Journal of Thoracic Oncology 18 ( 4) 436 -446
19
2023
Rendering fireworks displays
Teng-See Loke , Daniel Tan , Hock-Soon Seah , Meng-Hwa Er
IEEE Computer Graphics and Applications 12 ( 3) 33 -43
30
1992
Comparing virtual staining artificial intelligence model performance on same-tissue versus serial-tissue sections based on CD3+ T-cell ground truth
Abu Bakr Azam , Felicia Wee , Juha Väyrynen , Willa Wen-You Lim
bioRxiv 2023.11. 12.565422 -2023.11. 12.565422
2023
Abstract CT126: An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation
Daniel Tan , Koichi Goto , Herbert HF Loong , Tsung-Ying Yang
Cancer Research 83 ( 8_Supplement) CT126 -CT126
1
2023
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance
Egbert F Smit , Christophe Dooms , Jo Raskin , Ernest Nadal
Future Oncology
33
2021
Dissecting cellular heterogeneity using single cell RNA sequencing in human lung tumors
Elise T Courtois , Huipeng Li , Yuliana Tan , Daniel Tan
Cancer Research 77 ( 13 Supplement) 4496 -4496
2017
Single cell analysis of early metastasis identifies targetable tumor subpopulation and mechanisms of immune evasion in squamous cell cancers
Hong Sheng Quah , Elaine Yiqun Cao , Lisda Suteja , Hui Leong
2021
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ASIAN AND EUROPEAN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Gilberto DL Lopes Jr , Joel Segel , Daniel Tan , Young Do
JOURNAL OF THORACIC ONCOLOGY 6 ( 6) S1179 -S1179
2011
A COMPARATIVE CLINICAL AND COST-EFFECTIVENESS EVALUATION OF GEFITINIB AND ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
Gilberto DL Lopes Jr , Joel Segel , Daniel Tan , Young Do
JOURNAL OF THORACIC ONCOLOGY 6 ( 6) S1306 -S1307
2011
Motivations and experiences of patients with advanced cancer participating in Phase 1 clinical trials: A qualitative study
Grace Meijuan Yang , Wah Ying Ong , Jasmine Tan , Jiayan Ding
Palliative Medicine 37 ( 2) 257 -264
5
2023
Phase I/II study of MAK683 in patients with advanced malignancies, including diffuse large B-cell lymphoma
Vincent Ribrag , Jean-Marie Michot , Lara Igleias , Daniel Tan
Blood 138 1422 -1422
7
2021
A practical and adaptive approach to lung cancer screening: a review of international evidence and position on CT lung cancer screening in the Singaporean population by the College of Radiologists Singapore
Charlene Jin Yee Liew , Lester Chee Hao Leong , Lynette Li San Teo , Ching Ching Ong
Singapore medical journal 60 ( 11) 554 -554
4
2019
First-in-Human, Phase I Dose-Escalation Study of CGM097, a HDM2 Inhibitor in Adult Patients With p53 Wild-type Advanced Solid Malignancies
Sebastian Bauer , George Demetri , Sebastien Jeay , Reinhard Dummer
British journal of cancer: BJC 125 687 -698
2021